(BBIO) BridgeBio Pharma - Ratings and Ratios
Attruby, Infigratinib, Encaleret, BBP-418
BBIO EPS (Earnings per Share)
BBIO Revenue
Description: BBIO BridgeBio Pharma
BridgeBio Pharma Inc (NASDAQ:BBIO) is a commercial-stage biopharmaceutical company focused on developing transformative medicines for genetic diseases and cancers. The companys pipeline includes several promising candidates, such as Attruby for ATTR-CM, infigratinib for achondroplasia and hypochondroplasia, Encaleret for ADH1, and BBP-418 for LGMD2I/R9.
From a business perspective, BridgeBio Pharma has established strategic partnerships with notable companies, including Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University, Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. These collaborations can be seen as a vote of confidence in the companys research and development capabilities.
To evaluate the companys performance, we can look at key performance indicators (KPIs) such as revenue growth, R&D expenses as a percentage of revenue, and pipeline progress. With a market capitalization of $8.8 billion and a return on equity (ROE) of 49.21%, BridgeBio Pharma demonstrates a strong financial position. However, as a biopharmaceutical company, its profitability is not yet reflected in its P/E ratio, which is not available due to likely negative earnings.
Further analysis of the companys pipeline and partnerships reveals a strong focus on rare genetic diseases, which can provide a competitive advantage due to the potential for orphan drug designation and exclusivity. The progress of its candidates through clinical trials will be crucial in determining the companys future success. Key milestones to watch include the outcome of ongoing Phase 3 trials and potential FDA approvals.
Investors should monitor the companys cash burn rate, as R&D expenses are likely to remain significant. The companys ability to manage its finances effectively while advancing its pipeline will be essential in driving long-term value creation.
BBIO Stock Overview
| Market Cap in USD | 10,055m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2019-06-27 |
BBIO Stock Ratings
| Growth Rating | 74.3% |
| Fundamental | 45.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 61.5% |
| Analyst Rating | 4.37 of 5 |
BBIO Dividends
Currently no dividends paidBBIO Growth Ratios
| Growth Correlation 3m | 90.6% |
| Growth Correlation 12m | 92.7% |
| Growth Correlation 5y | -17.3% |
| CAGR 5y | 73.10% |
| CAGR/Max DD 3y | 1.49 |
| CAGR/Mean DD 3y | 3.30 |
| Sharpe Ratio 12m | 0.48 |
| Alpha | 0.00 |
| Beta | 0.996 |
| Volatility | 48.01% |
| Current Volume | 2160.9k |
| Average Volume 20d | 2087.8k |
| Stop Loss | 50.7 (-4.9%) |
| Signal | -0.37 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-776.4m TTM) > 0 and > 6% of Revenue (6% = 14.1m TTM) |
| FCFTA -0.48 (>2.0%) and ΔFCFTA 18.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 312.3% (prev 219.9%; Δ 92.38pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.61 (>3.0%) and CFO -655.8m > Net Income -776.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.19 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (190.5m) change vs 12m ago 1.56% (target <= -2.0% for YES) |
| Gross Margin 96.80% (prev 98.32%; Δ -1.52pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 25.16% (prev 27.58%; Δ -2.43pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.89 (EBITDA TTM -643.6m / Interest Expense TTM 132.7m) >= 6 (WARN >= 3) |
Altman Z'' -11.85
| (A) 0.68 = (Total Current Assets 912.3m - Total Current Liabilities 175.9m) / Total Assets 1.08b |
| (B) -3.19 = Retained Earnings (Balance) -3.45b / Total Assets 1.08b |
| warn (B) unusual magnitude: -3.19 — check mapping/units |
| (C) -0.69 = EBIT TTM -649.1m / Avg Total Assets 937.3m |
| (D) -1.21 = Book Value of Equity -3.45b / Total Liabilities 2.86b |
| Total Rating: -11.85 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 45.47
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -4.68% = -2.34 |
| 3. FCF Margin data missing |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda -2.89 = -2.50 |
| 7. RoE data missing |
| 8. Rev. Trend 70.59% = 5.29 |
| 9. EPS Trend 0.32% = 0.02 |
What is the price of BBIO shares?
Over the past week, the price has changed by -3.36%, over one month by +4.41%, over three months by +27.73% and over the past year by +91.47%.
Is BridgeBio Pharma a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BBIO is around 49.28 USD . This means that BBIO is currently overvalued and has a potential downside of -7.59%.
Is BBIO a buy, sell or hold?
- Strong Buy: 10
- Buy: 6
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BBIO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 64.6 | 21.1% |
| Analysts Target Price | 64.6 | 21.1% |
| ValueRay Target Price | 54.9 | 3% |
Last update: 2025-09-13 05:01
BBIO Fundamental Data Overview
CCE Cash And Equivalents = 757.3m USD (Cash And Short Term Investments, last quarter)
P/S = 42.642
P/B = 123.6828
Beta = 1.255
Revenue TTM = 235.8m USD
EBIT TTM = -649.1m USD
EBITDA TTM = -643.6m USD
Long Term Debt = 1.85b USD (from longTermDebt, last quarter)
Short Term Debt = 9.59m USD (from shortTermDebt, last quarter)
Debt = 1.86b USD (Calculated: Short Term 9.59m + Long Term 1.85b)
Net Debt = 1.93b USD (from netDebt column, last quarter)
Enterprise Value = 11.16b USD (10.06b + Debt 1.86b - CCE 757.3m)
Interest Coverage Ratio = -4.89 (Ebit TTM -649.1m / Interest Expense TTM 132.7m)
FCF Yield = -4.68% (FCF TTM -521.7m / Enterprise Value 11.16b)
FCF Margin = -221.2% (FCF TTM -521.7m / Revenue TTM 235.8m)
Net Margin = -329.3% (Net Income TTM -776.4m / Revenue TTM 235.8m)
Gross Margin = 96.80% ((Revenue TTM 235.8m - Cost of Revenue TTM 7.56m) / Revenue TTM)
Tobins Q-Ratio = -3.24 (set to none) (Enterprise Value 11.16b / Book Value Of Equity -3.45b)
Interest Expense / Debt = 2.02% (Interest Expense 37.6m / Debt 1.86b)
Taxrate = 21.0% (US default)
NOPAT = -649.1m (EBIT -649.1m, no tax applied on loss)
Current Ratio = 5.19 (Total Current Assets 912.3m / Total Current Liabilities 175.9m)
Debt / EBITDA = -2.89 (Net Debt 1.93b / EBITDA -643.6m)
Debt / FCF = -3.56 (Debt 1.86b / FCF TTM -521.7m)
Total Stockholder Equity = -1.53b (last 4 quarters mean)
RoA = -71.88% (Net Income -776.4m, Total Assets 1.08b )
RoE = unknown (Net Income TTM -776.4m / Total Stockholder Equity -1.53b)
RoCE = -203.8% (set to none) (Ebit -649.1m / (Equity -1.53b + L.T.Debt 1.85b))
RoIC = -258.5% (set to none) (NOPAT -649.1m / Invested Capital 251.1m)
WACC = 8.42% (E(10.06b)/V(11.91b) * Re(9.68%)) + (D(1.86b)/V(11.91b) * Rd(2.02%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 2.33%
Discount Rate = 9.68% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -521.7m)
EPS Correlation: 0.32 | EPS CAGR: -1.37% | SUE: -0.56 | # QB: 0
Revenue Correlation: 70.59 | Revenue CAGR: 721.2% | SUE: 0.29 | # QB: 0
Additional Sources for BBIO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle